Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | Senior Vice President | December 31, 2004 | February 14, 2005 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | November 08, 2018 | November 09, 2018 |
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2025 | July 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date December 31, 2004 · Filed February 14, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,316 |
Ending reported balance
After 2004-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2004-09-16 · Gift · Disposed 16 · Balance 106,395 Row 2 · 2004-09-23 · Gift · Disposed 79 · Balance 106,316 |
| Common StockSEC Table I · non-derivative | Indirect2002-4 GRAT | 22,760 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 22,760 F1: Grantor retained annuity trust established by reporting person. Reporting person is trustee. |
| Common StockSEC Table I · non-derivative | Indirect401(k) plan | 18,991 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 18,991 |
| Common StockSEC Table I · non-derivative | IndirectCRUT 2002 | 11,970 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,970 F2: Held by charitable remainder trust of which reporting person is trustee and sole non-charitable beneficiary. Reporting person disclaims beneficial ownership in the shares held by the CRUT, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectfamily ltd. partnership | 44,433 |
Reported balance
Holding disclosure · report date 2004-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 44,433 F3: Family limited partnership of which reporting person is sole general partner. Reporting disclaims beneficial ownership of the sh ares held by the partnership except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Grantor retained annuity trust established by reporting person. Reporting person is trustee.
F2: Held by charitable remainder trust of which reporting person is trustee and sole non-charitable beneficiary. Reporting person disclaims beneficial ownership in the shares held by the CRUT, except to the extent of his pecuniary interest therein.
F3: Family limited partnership of which reporting person is sole general partner. Reporting disclaims beneficial ownership of the sh ares held by the partnership except to the extent of his pecuniary interest therein.
HAEMONETICS CORP
Report date November 08, 2018 · Filed November 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,335 |
Reported balance
After 2018-11-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-08 · Sale · Disposed 12,322 · Balance 15,335 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2: This number includes unvested restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2: This number includes unvested restricted stock units previously reported.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2025 · Filed July 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2025-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 30,000 · Balance 30,000 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 54,734 |
Reported balance
After 2025-06-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-06-18 · Grant · Acquired 24,734 · Balance 54,734 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $70,000. The RSUs will vest in full on June 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.14 | $5,714.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 5 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,081 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.15 | $5,715.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 4 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,981 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $57.17 | $11,434.00 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 3 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,781 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 18 | $57.18 | $1,029.24 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,763 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $57.23 | $5,722.50 |
DisclosureSEC source: 0001127602-17-033796 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,663 Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024397 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,663 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| September 23, 2004 Filed Feb 14, 2005 23:49 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 79 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000049 · doc5.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,316 Read SEC document |
| September 16, 2004 Filed Feb 14, 2005 23:49 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 16 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-05-000049 · doc5.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,395 Read SEC document |
| February 17, 2004 Filed Feb 19, 2004 19:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantEmployee stock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $73.11 | $0.00 |
DisclosureSEC source: 0000059478-04-000071 · doc4.xml · derivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2014-02-14 Read SEC document |
| November 12, 2003 Filed Feb 17, 2004 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000034 · doc5.xml · nonDerivative · entry 4 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,559 Read SEC document |
| November 05, 2003 Filed Feb 17, 2004 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 71 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000034 · doc5.xml · nonDerivative · entry 3 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,560 Read SEC document |
| July 28, 2003 Filed Feb 17, 2004 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 75 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000034 · doc5.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,631 Read SEC document |
| June 19, 2003 Filed Feb 17, 2004 19:46 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 123 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-04-000034 · doc5.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,706 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.